Albumedix and Eleven Biotherapeutics Announce Albumin Variant Technology Agreement

Jounce Therapeutics Appoints Perry Karsen to its Board of Directors

CytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone

Zafgen\'s Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints

Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis